<DOC>
	<DOCNO>NCT01928537</DOCNO>
	<brief_summary>This study examine effect intravenously administer rigosertib relationship bone marrow blast response overall survival myelodysplastic syndrome ( MDS ) patient 5-30 % bone marrow blast progress treatment azacitidine decitabine .</brief_summary>
	<brief_title>Efficacy Safety IV Rigosertib MDS Patients With Excess Blasts Progressing After Azacitidine Decitabine</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis MDS confirm within 6 week prior Screening accord WHO criteria FrenchAmericanBritish ( FAB ) classification . MDS classify follow , accord WHO criteria FAB classification : RAEB1 ( 5 % 9 % BM blast ) RAEB2 ( 10 % 19 % BM blast ) CMML ( 10 % 20 % BM blast ) white blood cell ( WBC ) &lt; 13,000/μL RAEBt ( 20 % 30 % BM blast ) , meet follow criterion : WBC &lt; 25,000/μL study entry ; , Stable White Blood Cell ( WBC ) least 4 week prior Screening require intervention WBC control hydroxyurea , chemotherapy , leukopheresis . At least one cytopenia ( Absolute Neutrophil Count ( ANC ) &lt; 1800/μL Platelet ( PLT ) count &lt; 100,000/μL hemoglobin ( Hgb ) &lt; 10 g/dL ) . Progression ( accord 2006 IWG criterion ) time initiation subcutaneous intravenous azacitidine decitabine treatment per label past 2 year , define follow : For patient ˂ 5 % BMBL , ≥ 50 % increase BMBL ˃ 5 % BMBL For patient 510 % BMBL , ≥ 50 % increase BMBL ˃ 10 % BMBL For patient 1020 % BMBL , ≥ 50 % increase BMBL ˃ 20 % BMBL For patient 2030 % BMBL , ≥ 50 % increase BMBL ˃ 30 % BMBL Any following : ≥ 50 % decrease maximum remission/response level granulocytes PLT ; Decrease Hgb concentration ≥ 2 g/dL ; , Transfusion dependence , define administration least 4 RBC unit past 8 week Screening ( patient must Hgb value ˂ 9 g/dL prior transfusion consider ) , absence another explanation . Has fail respond , relapse following , eligible , opted participate bone marrow transplantation . Off treatment MDS least 4 week , except azacitidine decitabine . Filgrastim ( GCSF ) erythropoietin allow study clinically indicate . No medical need induction chemotherapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Willing adhere prohibition restriction specify protocol . Patient must sign informed consent form . Previous participation clinical study IV oral rigosertib . Anemia due factor MDS ( include hemolysis gastrointestinal [ GI ] bleed ) unless stabilize 1 week RBC transfusion . Any active malignancy within past year , except basal cell squamous cell skin cancer carcinoma situ cervix breast . Uncontrolled intercurrent illness include . Active infection adequately respond appropriate therapy . Total bilirubin ≥ 1.5 mg/dL relate hemolysis Gilbert 's disease . ALT/AST ≥ 2.5 x upper limit normal ( ULN ) . Serum creatinine ≥ 2.0 mg/dL . Ascites require active medical management include paracentesis , hyponatremia ( define serum sodium value &lt; 130 mEq/L ) . Female patient pregnant lactate . Patients unwilling follow strict contraception requirement . Female patient reproductive potential negative urine betahuman chorionic gonadotropin ( βHCG ) pregnancy test Screening . Major surgery without full recovery major surgery within 3 week Baseline/Cycle 1 Day 1 visit . Uncontrolled hypertension ( define systolic pressure ≥160 mmHg and/or diastolic pressure ≥ 110 mmHg ) . New onset seizure ( within 3 month prior Baseline ) poorly control seizure . Any concurrent investigational agent chemotherapy , radiotherapy , immunotherapy . Prior treatment lowdose cytarabine past 2 year . Investigational therapy within 4 week Baseline/Day 1 visit . Psychiatric illness social situation would limit patient 's ability tolerate and/or comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>International Working Group</keyword>
	<keyword>azacitidine</keyword>
	<keyword>decitabine</keyword>
</DOC>